{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T14:15:01Z","timestamp":1773411301221,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:00:00Z","timestamp":1770508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["15560"],"award-info":[{"award-number":["15560"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Phys"],"DOI":"10.1186\/s40658-026-00842-y","type":"journal-article","created":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T08:14:58Z","timestamp":1770538498000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Segmentation method comparison for baseline [18F]FDG PET-CT in follicular lymphoma patients"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1624-5250","authenticated-orcid":false,"given":"Anouk D. M.","family":"Nijman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanne E.","family":"Wiegers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerben J. C.","family":"Zwezerijnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Verweij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne L.","family":"Bes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"H\u00fcttmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"D\u00fchrsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Kurch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie Jos\u00e9","family":"Kersten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martijn W.","family":"Heymans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9e M.","family":"Zijlstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Boellaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,8]]},"reference":[{"key":"842_CR1","unstructured":"Nederlandse Kankerregistratie (NKR). Incidentie per jaar, Aantal [Available from: nkr-cijfers.inknl.nl]."},{"issue":"1","key":"842_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00277-017-3151-2","volume":"97","author":"T Fischer","year":"2018","unstructured":"Fischer T, Zing NPC, Chiattone CS, Federico M, Luminari S. Transformed follicular lymphoma. Ann Hematol. 2018;97(1):17\u201329.","journal-title":"Ann Hematol"},{"issue":"12","key":"842_CR3","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German low-grade lymphoma study group. Blood. 2005;106(12):3725\u201332.","journal-title":"Blood"},{"issue":"10","key":"842_CR4","doi-asserted-by":"publisher","first-page":"3338","DOI":"10.3324\/haematol.2023.284538","volume":"109","author":"A Barraclough","year":"2024","unstructured":"Barraclough A, Agrawal S, Talaulikar D, Chong G, Yoo E, Cheah CY, et al. Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian lymphoma alliance study. Haematologica. 2024;109(10):3338\u201345.","journal-title":"Haematologica"},{"issue":"3","key":"842_CR5","first-page":"202","volume":"41","author":"A Diaz-Silvan","year":"2022","unstructured":"Diaz-Silvan A, Oton-Sanchez LF, Caresia-Aroztegui AP, Del Puig Cozar-Santiago M, Orcajo-Rincon J, de Arcocha-Torres M, et al. Clinical application of [18F]FDG PET\/CT in follicular lymphoma. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2022;41(3):202\u201312.","journal-title":"Elsevier Espana"},{"key":"842_CR6","doi-asserted-by":"crossref","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32(27):3048\u201358.","DOI":"10.1200\/JCO.2013.53.5229"},{"issue":"23","key":"842_CR7","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national lymphocare study. J Clin Oncol. 2015;33(23):2516\u201322.","journal-title":"J Clin Oncol"},{"issue":"1","key":"842_CR8","doi-asserted-by":"publisher","first-page":"8033","DOI":"10.1038\/s41598-024-58412-0","volume":"14","author":"S Draye-Carbonnier","year":"2024","unstructured":"Draye-Carbonnier S, Camus V, Becker S, Tonnelet D, Leveque E, Zduniak A, et al. Prognostic value of the combination of volume, massiveness and fragmentation parameters measured on baseline FDG pet in high-burden follicular lymphoma. Sci Rep. 2024;14(1):8033.","journal-title":"Sci Rep"},{"key":"842_CR9","first-page":"13","volume":"13","author":"C Durot","year":"2023","unstructured":"Durot C, Durot E, Mule S, Morland D, Godard F, Quinquenel A, et al. Pretreatment CT texture parameters as predictive biomarkers of progression-free survival in follicular lymphoma treated with immunochemotherapy and rituximab maintenance. Diagnostics (Basel). 2023;13:13.","journal-title":"Diagnostics (Basel)"},{"issue":"30","key":"842_CR10","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","volume":"34","author":"M Meignan","year":"2016","unstructured":"Meignan M, Cottereau AS, Versari A, Chartier L, Dupuis J, Boussetta S, et al. Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies. J Clin Oncol. 2016;34(30):3618\u201326.","journal-title":"J Clin Oncol"},{"issue":"1","key":"842_CR11","doi-asserted-by":"publisher","first-page":"e70010","DOI":"10.1002\/hon.70010","volume":"43","author":"A Zduniak","year":"2025","unstructured":"Zduniak A, Leveque E, Draye-Carbonnier S, Becker S, Tonnelet D, Dubois S, et al. Combining total metabolic tumor volume with beta-2-microglobulin levels predicts outcomes in high-burden follicular lymphoma patients. Hematol Oncol. 2025;43(1):e70010.","journal-title":"Hematol Oncol"},{"key":"842_CR12","doi-asserted-by":"publisher","first-page":"943151","DOI":"10.3389\/fonc.2022.943151","volume":"12","author":"H Li","year":"2022","unstructured":"Li H, Wang M, Zhang Y, Hu F, Wang K, Wang C, et al. Prediction of prognosis and pathologic grade in follicular lymphoma using 18F-FDG PET\/CT. Front Oncol. 2022;12:943151.","journal-title":"Front Oncol"},{"key":"842_CR13","doi-asserted-by":"crossref","unstructured":"Maccora D, Guerreri M, Malafronte R, D\u2019Alo F, Hohaus S, De Summa M et al. The predictive role of baseline 18F-FDG PET\/CT radiomics in follicular lymphoma on watchful waiting: a preliminary study. Diagnostics. 2025;15(4):432.","DOI":"10.3390\/diagnostics15040432"},{"issue":"3","key":"842_CR14","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1007\/s00259-021-05480-3","volume":"49","author":"JJ Eertink","year":"2022","unstructured":"Eertink JJ, van de Brug T, Wiegers SE, Zwezerijnen GJC, Pfaehler EAG, Lugtenburg PJ, et al. 18F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2022;49(3):932\u201342.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"842_CR15","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2967\/jnumed.121.262117","volume":"63","author":"JJ Eertink","year":"2022","unstructured":"Eertink JJ, Pfaehler EAG, Wiegers SE, van Brug T, Lugtenburg D. Quantitative radiomics features in diffuse large B-cell lymphoma: does segmentation method matter? J Nucl Med. 2022;63(3):389\u201395.","journal-title":"J Nucl Med"},{"key":"842_CR16","doi-asserted-by":"crossref","unstructured":"Malmon S, Elsensohn MH, Thieblemont C, Morschhauser F, Casasnovas O, Andre M et al. Prognostic impact of metabolic tumor volume using the SUV4.0 segmentation threshold in 1,960 lymphoma patients from prospective LYSA trials. Eur J Nucl Med Mol Imaging. 2025.","DOI":"10.1007\/s00259-025-07176-4"},{"issue":"4","key":"842_CR17","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1007\/s10278-023-00823-y","volume":"36","author":"CS Constantino","year":"2023","unstructured":"Constantino CS, Leocadio S, Oliveira FPM, Silva M, Oliveira C, Castanheira JC, et al. Evaluation of semiautomatic and deep learning-based fully automatic segmentation methods on [18F]FDG PET\/CT images from patients with lymphoma: influence on tumor characterization. J Digit Imaging. 2023;36(4):1864\u201376.","journal-title":"J Digit Imaging"},{"issue":"2","key":"842_CR18","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"842_CR19","doi-asserted-by":"crossref","unstructured":"Boellaard R, Buvat I, Nioche C, Ceriani L, Cottereau AS, Guerra L, et al. International benchmark for total metabolic tumor volume measurement in baseline 18F-FDG PET\/CT of lymphoma patients: a milestone toward clinical implementation. J Nucl Med. 2024;65(9):1343\u20138.","DOI":"10.2967\/jnumed.124.267789"},{"issue":"7","key":"842_CR20","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1007\/s00259-018-3953-z","volume":"45","author":"H Ilyas","year":"2018","unstructured":"Ilyas H, Mikhaeel NG, Dunn JT, Rahman F, Moller H, Smith D, et al. Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma. Eur J Nucl Med Mol Imaging. 2018;45(7):1142\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"842_CR21","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1148\/radiol.14132807","volume":"273","author":"V Frings","year":"2014","unstructured":"Frings V, van Velden FH, Velasquez LM, Hayes W, van de Ven PM, Hoekstra OS, et al. Repeatability of metabolically active tumor volume measurements with FDG PET\/CT in advanced gastrointestinal malignancies: a multicenter study. Radiology. 2014;273:539\u201348.","journal-title":"Radiology"},{"issue":"12","key":"842_CR22","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1007\/s00259-011-1899-5","volume":"38","author":"P Cheebsumon","year":"2011","unstructured":"Cheebsumon P, Yaqub M, van Velden FH, Hoekstra OS, Lammertsma AA, Boellaard R. Impact of [18F]FDG PET imaging parameters on automatic tumour delineation: need for improved tumour delineation methodology. Eur J Nucl Med Mol Imaging. 2011;38(12):2136\u201344.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"842_CR23","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.2967\/jnumed.120.258673","volume":"62","author":"GJC Zwezerijnen","year":"2021","unstructured":"Zwezerijnen GJC, Eertink JJ, Burggraaff CN, Wiegers SE, Shaban E, Pieplenbosch S, et al. Interobserver agreement on automated metabolic tumor volume measurements of Deauville score 4 and 5 lesions at interim 18F-FDG PET in diffuse large B-Cell lymphoma. J Nucl Med. 2021;62(11):1531\u20136.","journal-title":"J Nucl Med"},{"issue":"5","key":"842_CR24","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00259-015-3239-7","volume":"43","author":"A Schaefer","year":"2016","unstructured":"Schaefer A, Vermandel M, Baillet C, Dewalle-Vignion AS, Modzelewski R, Vera P, et al. Impact of consensus contours from multiple PET segmentation methods on the accuracy of functional volume delineation. Eur J Nucl Med Mol Imaging. 2016;43(5):911\u201324.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"842_CR25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13550-019-0481-1","volume":"9","author":"GD Kolinger","year":"2019","unstructured":"Kolinger GD, Vallez Garcia D, Kramer GM, Frings V, Smit EF, de Langen AJ, et al. Repeatability of [18F]FDG PET\/CT total metabolic active tumour volume and total tumour burden in NSCLC patients. EJNMMI Res. 2019;9(1):14.","journal-title":"EJNMMI Res"},{"issue":"12","key":"842_CR26","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2967\/jnumed.122.264063","volume":"63","author":"LK Shiyam Sundar","year":"2022","unstructured":"Shiyam Sundar LK, Yu J, Muzik O, Kulterer OC, Fueger B, Kifjak D, et al. Fully automated, semantic segmentation of whole-body 18F-FDG PET\/CT images based on data-centric artificial intelligence. J Nucl Med. 2022;63(12):1941\u20138.","journal-title":"J Nucl Med"},{"issue":"2","key":"842_CR27","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1200\/JCO.18.00400","volume":"37","author":"C Sarkozy","year":"2019","unstructured":"Sarkozy C, Maurer MJ, Link BK, Ghesquieres H, Nicolas E, Thompson CA, et al. Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts. J Clin Oncol. 2019;37(2):144\u201352.","journal-title":"J Clin Oncol"},{"key":"842_CR28","doi-asserted-by":"crossref","unstructured":"Stevens WBC, Bakunina K, Cuijpers M, Chamuleau M, Beeker A, Fijnheer R, et al. HOVON110\/ReBeL study: results of the phase I part of a randomized phase I\/II study of Lenalidomide, rituximab with or without bendamustine in patients with relapsed\/refractory follicular lymphoma. HemaSphere. 2020;4(1):e325","DOI":"10.1097\/HS9.0000000000000325"},{"issue":"20","key":"842_CR29","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1200\/JCO.2017.76.8093","volume":"36","author":"U Duhrsen","year":"2018","unstructured":"Duhrsen U, Muller S, Hertenstein B, Thomssen H, Kotzerke J, Mesters R, et al. Positron emission tomography-guided therapy of aggressive Non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial. J Clin Oncol. 2018;36(20):2024\u201334.","journal-title":"J Clin Oncol"},{"key":"842_CR30","unstructured":"Boellaard R. Quantitative oncology molecular analysis suite: ACCURATE. 2018. Contract No.: supplement 1."},{"issue":"3","key":"842_CR31","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2967\/jnumed.119.238923","volume":"62","author":"SF Barrington","year":"2021","unstructured":"Barrington SF, Zwezerijnen B, de Vet HCW, Heymans MW, Mikhaeel NG, Burggraaff CN, et al. Automated segmentation of baseline metabolic total tumor burden in diffuse large B-cell lymphoma: which method is most successful? A study on behalf of the PETRA consortium. J Nucl Med. 2021;62(3):332\u20137.","journal-title":"J Nucl Med"},{"key":"842_CR32","unstructured":"Shiyam L, Pires M, Gutschmayer S. LalithShiyam\/LION: lionz-v.0.9.1 (lionz-v.0.9.1) Zenodo2024."},{"key":"842_CR33","doi-asserted-by":"crossref","unstructured":"Ferr\u00e1ndez MC, Golla SSV, De Visser SCA, Eertink JJ, Lugtenburg PJ, Wiegers SE, et al. Evaluation of an artificial intelligence method for lesion segmentation of baseline FDG PET studies of DLBCL patients. Available at Research Square. 2025.","DOI":"10.21203\/rs.3.rs-6294601\/v1"},{"issue":"1","key":"842_CR34","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13550-022-00916-9","volume":"12","author":"MC Ferrandez","year":"2022","unstructured":"Ferrandez MC, Eertink JJ, Golla SSV, Wiegers SE, Zwezerijnen GJC, Pieplenbosch S, et al. Combatting the effect of image reconstruction settings on lymphoma [18F]FDG PET metabolic tumor volume assessment using various segmentation methods. EJNMMI Res. 2022;12(1):44.","journal-title":"EJNMMI Res"},{"issue":"4","key":"842_CR35","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1007\/s11307-020-01474-z","volume":"22","author":"CN Burggraaff","year":"2020","unstructured":"Burggraaff CN, Rahman F, Kassner I, Pieplenbosch S, Barrington SF, Jauw YWS, et al. Optimizing workflows for fast and reliable metabolic tumor volume measurements in diffuse large B cell lymphoma. Mol Imaging Biol. 2020;22(4):1102\u201310.","journal-title":"Mol Imaging Biol"},{"issue":"8","key":"842_CR36","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.2967\/jnumed.119.227249","volume":"60","author":"SF Barrington","year":"2019","unstructured":"Barrington SF, Meignan M. Time to prepare for risk adaptation in lymphoma by standardizing measurement of metabolic tumor burden. J Nucl Med. 2019;60(8):1096\u2013102.","journal-title":"J Nucl Med"},{"issue":"8","key":"842_CR37","doi-asserted-by":"publisher","first-page":"6616","DOI":"10.21037\/qims-2024-2740","volume":"15","author":"JD Oldan","year":"2025","unstructured":"Oldan JD, Jensen CE, Stephens DM, Grover NS, Beaven AW, Dittus CE, et al. Comparison of standardized uptake value and standardized uptake lean body mass metrics in 18F-fluorodeoxyglucose positron emission tomography for assessing transformation in chronic lymphocytic leukemia and follicular lymphoma. Quant Imaging Med Surg. 2025;15(8):6616\u201326.","journal-title":"Quant Imaging Med Surg"}],"container-title":["EJNMMI Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40658-026-00842-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40658-026-00842-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40658-026-00842-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T10:08:29Z","timestamp":1773396509000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40658-026-00842-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,8]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["842"],"URL":"https:\/\/doi.org\/10.1186\/s40658-026-00842-y","relation":{},"ISSN":["2197-7364"],"issn-type":[{"value":"2197-7364","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,8]]},"assertion":[{"value":"13 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The HOVON110 study go approval by the Amsterdam UMC ethical review board. The PETAL study was approved by the German Federal Institute for Drugs and Medical Devices and the ethics committees of the participating centers.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}